Value-based incentive programs (VBIPs) aim to drive improvements in quality and reduce costs by linking financial incentives or penalties to hospital performance. Two VBIPs, the Hospital Value-Based Purchasing (VBP) Program and the Hospital-Acquired Condition Reduction Program (HACRP), target health care-associated infections reported to the Centers for Disease Control and Prevention's National Healthcare Safety Network. We evaluated the association between these VBIPs and catheter-associated urinary tract infections (CAUTIs) in the critical care setting.
Methods | An interrupted time series design was used to examine the association between VBIPs and 3 CAUTI-related quality measures: device-associated infection rates (CAUTIs per 1000 indwelling urinary catheter-days), population-based infection rates (CAUTIs per 1000 patient-days), and indwelling urinary catheter device use (catheter-days per patient-days). We used National Healthcare Safety Network data from 2013 to 2017 for adults in nonfederal acute care hospitals that were subject to the inpatient prospective payment system and therefore eligible for HACRP and Hospital VBP Program incentives and penalties. 1 We focused on intensive care units (ICUs) because CAUTI surveillance was not mandated for non-ICUs until 2015 and VBIPs did not target non-ICU CAUTIs until fiscal year 2018. Using patient-level case reports, we calculated unit-level CAUTI rates that included only cases associated with urine cultures growing at least 100 000 colony-forming units of bacteria per milliliter, and excluded cases associated with nonbacterial organisms or lower-growth bacteria, per the January 2015 National Healthcare Safety Network surveillance case definition revision. 2 Hospital characteristics were collected from the 2015
American Hospital Association (AHA) annual survey. We used generalized estimating equations with robust sandwich variance estimators to fit negative binomial models for infection rates and logistic regression models for device use to assess for changes in level and trend after VBIP implementation, accounting for hospital-level and unit-level clustering. Models included time, a post-VBIP implementation indicator (after October 1, 2015), and a 2-way interaction term with an a priori-defined VBIP implementation roll-in period (October 1, 2014 -September 30, 2015 to account for the lag between the onset of the HACRP and the Hospital VBP Program payment adjustments. We considered 2-sided P<.05 to be statistically significant and used SAS version 9.4 (SAS Institute) for all analyses. The Harvard Pilgrim Health Care Institute Institutional Review Board approved this study with a waiver of informed consent.
Results | The sample included 592 hospitals from 49 states and the District of Columbia, contributing 22 572 494 patientdays and 13 607 240 indwelling urinary catheter-days from 1185 ICUs. Compared with the hospitals with intensive care services subject to the inpatient prospective payment system included in the 2015 AHA annual survey, study hospitals were larger (≥400 beds) teaching hospitals located in the Northeast and in metropolitan areas (Table) .
Value-based incentive program implementation was not significantly associated with immediate changes or changes in trend for any outcome (Figure) . The device-associated CAUTI rate was stable before VBIP implementation and significantly declined by 1% per quarter after implementation, but the change in slope was not significant. Population-based rates and device use declined significantly by 2% per quarter before and after implementation, without significant changes in slope.
Discussion | Federal VBIPs were not associated with reductions in device-associated CAUTI rates, the outcome incorporated into the VBIP scoring on which hospitals are graded. Value-based incentive program implementation was also not associated with changes in already declining populationbased CAUTI rates or device use, measures that may more directly reflect CAUTI prevention efforts to decrease indwelling urinary catheter use.
3
Study limitations include the primary focus on ICUs, although VBIPs did not explicitly target CAUTIs in non-ICUs until 2018. Limitations also include the need to confine analyses to a single health care-associated infection because revisions in surveillance case definitions and procedures for additional outcomes could not definitively be accounted for. This study's negative findings may reflect the priority placed on CAUTI prevention in the decade preceding VBIP implementation. [4] [5] [6] In addition, VBIPs target numerous process, outcome, patient satisfaction, and composite measures, potentially limiting the ability to detect a significant population-level improvement in a single outcome. Nonetheless, the findings call into question the effectiveness of VBIPs for catalyzing improvements in care quality and underscore the importance of ongoing rigorous policy evaluations. Working with patients with nonmedical opioid use not only requires expertise and teamwork but also resources and patience. Burnout among palliative care clinicians is already at a high level.
5 As palliative care teams strive to see more patients with complex care needs earlier in the disease trajectory, a proportionate investment in resources to support these teams will be needed. There is already an inadequate supply of palliative care specialists and addiction specialists in the United States. Referral to addiction medicine is not always realistic for patients on active cancer treatments or in the last months of life. We are concerned that insufficient resources may contribute to the collapse of existing palliative care programs and burnout among clinicians, which could further compound the opioid crisis.
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